VERO Venus Concept

Venus Concept Announces Senior Management Changes

Venus Concept Announces Senior Management Changes

TORONTO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced several changes to its senior leadership team.

Dr. Hemanth Varghese, President and COO will depart the company to pursue other opportunities, effective March 28, 2025, and Bill McGrail, EVP, Technical Operations & Compliance, will retire, effective February 28, 2025. The Company expresses their gratitude for their contribution to Venus’ turnaround and drive for operational excellence globally.

With the departures, Kirk Gunhus has been appointed Chief Revenue Officer, with global responsibility for Venus’ sales efforts. This includes oversight of the direct field force, distributor relationships and technical support for all customers. Ross Portaro has been appointed as EVP, Commercial Strategy and Head of Venus Hair, with a focus on providing commercial guidance and expanding our Venus Hair business in all jurisdictions.

Venus Concept also welcomes back Melissa Kang, the Company’s former EVP, Global Marketing & Product Management, as Chief Product Officer. She will work on continuing the history of innovation at the Company, by guiding future product vision and roadmap. Michael Mandarello, the Company’s Chief Legal Officer, will take on an expanded role as Head of Strategy & Operations, to include oversight of Venus’ corporate strategy and operational execution.

These changes are part of Venus Concept’s ongoing transformation efforts and are focused on establishing the optimal senior management structure for the next phase of its evolution.

"This new management structure is designed to streamline decision making and best position the Company for its return to growth and its journey towards profitability. This reorganization demonstrates our commitment to building the right team to enable future growth and maximize upcoming new product launches. I look forward to working with Kirk, Ross, Melissa and Michael in their new roles,” said Rajiv De Silva, Chief Executive Officer of Venus Concept.

Mr. De Silva went on to say, "We are grateful for the pivotal role Hemanth has played in executing the Company’s transformation efforts over the last two years and we wish him well in his future endeavors. We also congratulate Bill on his well-deserved retirement."

About Venus Concept

Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 12 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa PRO, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.



Investor Relations Contact:

ICR Westwicke on behalf of Venus Concept:

Mike Piccinino, CFA

 
EN
25/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Venus Concept

 PRESS RELEASE

Venus Concept Announces Second Quarter 2025 Financial Results

Venus Concept Announces Second Quarter 2025 Financial Results TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2025. Summary of Financial Results & Recent Progress: Total revenue for the second quarter of $15.7 million, down 5% year-over-year and up 15% quarter-over-quarter U.S. revenue up $0.4 million, or 5%, year-over-year driven by growth in cash systems sales of $1.0 million, or 23%, year...

 PRESS RELEASE

Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial ...

Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025 TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2025 financial results will be released after the market closes on Thursday, August 14, 2025. Management will host a conference call at 5:00 p.m. Eastern Time on August 14, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to partici...

 PRESS RELEASE

Venus Concept Announces $6.5 Million Debt-to-Equity Exchange Transacti...

Venus Concept Announces $6.5 Million Debt-to-Equity Exchange Transaction Further reduction of outstanding debt by Madryn Asset Management improves the Company’s balance sheet position TORONTO, July 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that, on June 30, 2025, the Company exchanged $6.5 million of its subordinated convertible notes held by affiliates of Madryn Asset Management, LP (“Madryn”) for 325,651 shares of its Series Y preferred stock. Following the transactio...

 PRESS RELEASE

Venus Concept Announces Closing of Up To $3.45 Million Registered Dire...

Venus Concept Announces Closing of Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules $1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants TORONTO, June 09, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of ...

 PRESS RELEASE

Venus Concept Announces Up To $3.45 Million Registered Direct Offering...

Venus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules $1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 434,720 shares of common stock at a purchase price of $2.65 per share i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch